Literature DB >> 30014466

Reduced expression of the RNA-binding protein HuD in pancreatic neuroendocrine tumors correlates with low p27Kip1 levels and poor prognosis.

Chongtae Kim1, Da Eun Jeong2, Sungeun Heo2, Eunbyul Ji1, Jun Gi Rho2, Myeongwoo Jung1, Sojin Ahn1, Ye-Jin Kim2, Yong-Sung Kim2, Suk Woo Nam3, Rohit N Kulkarni4, Kyoung Bun Lee5, Eun Kyung Lee1, Wook Kim2.   

Abstract

For the majority of patients diagnosed with pancreatic neuroendocrine tumors (NETs), there is significant malignant potential with a poor prognosis; however, the molecular abnormalities and pathogenesis of pancreatic NETs have not been firmly established. Here, we report that loss of expression of the RNA-binding protein HuD correlates with low p27Kip1 (p27) levels and poor prognosis in pancreatic NETs. HuD expression was frequently lost in many human pancreatic NETs, and these pancreatic NETs showed aggressive clinicopathological phenotypes with low p27 levels, increased tumor size, higher World Health Organization grade and pT stage of the tumor, and the presence of angioinvasion. Furthermore, loss of HuD was an independent, progression-free prognostic factor in multivariate survival analysis. However, the level of HuR, a member of the same Hu protein family as HuD, was not significantly correlated with pancreatic NET size and progression. Mechanistically, HuD enhanced p27 mRNA translation by interacting with both the 5'-untranslated region (UTR) and the 3'-UTR of p27 mRNA, and consequently suppressed cell cycle progression and tumor growth. In addition, HuD competed with miR-30a-3p for binding to the 3'-UTR of p27 mRNA, suggesting an interplay between HuD and miR-30a-3p in controlling p27 translation. Our results identify HuD as a pivotal suppressor of pancreatic NET growth, and suggest that HuD has potential value as a prognostic factor of pancreatic NETs.
Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  HuD; RNA-binding protein; p27Kip1; pancreatic neuroendocrine tumor; prognosis

Mesh:

Substances:

Year:  2018        PMID: 30014466      PMCID: PMC6150781          DOI: 10.1002/path.5135

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  41 in total

Review 1.  HuR and mRNA stability.

Authors:  C M Brennan; J A Steitz
Journal:  Cell Mol Life Sci       Date:  2001-02       Impact factor: 9.261

2.  Menin represses tumorigenesis via repressing cell proliferation.

Authors:  Ting Wu; Xianxin Hua
Journal:  Am J Cancer Res       Date:  2011-05-16       Impact factor: 6.166

3.  RNA-binding protein HuD controls insulin translation.

Authors:  Eun Kyung Lee; Wook Kim; Kumiko Tominaga; Jennifer L Martindale; Xiaoling Yang; Sarah S Subaran; Olga D Carlson; Evi M Mercken; Rohit N Kulkarni; Wado Akamatsu; Hideyuki Okano; Nora I Perrone-Bizzozero; Rafael de Cabo; Josephine M Egan; Myriam Gorospe
Journal:  Mol Cell       Date:  2012-03-01       Impact factor: 17.970

4.  Cannabinoids induce pancreatic β-cell death by directly inhibiting insulin receptor activation.

Authors:  Wook Kim; Qizong Lao; Yu-Kyong Shin; Olga D Carlson; Eun Kyung Lee; Myriam Gorospe; Rohit N Kulkarni; Josephine M Egan
Journal:  Sci Signal       Date:  2012-03-20       Impact factor: 8.192

5.  p27 Regulates the transition of beta-cells from quiescence to proliferation.

Authors:  Senta Georgia; Anil Bhushan
Journal:  Diabetes       Date:  2006-11       Impact factor: 9.461

6.  Translational control of p27Kip1 accumulation during the cell cycle.

Authors:  L Hengst; S I Reed
Journal:  Science       Date:  1996-03-29       Impact factor: 47.728

7.  Involvement of Hu and heterogeneous nuclear ribonucleoprotein K in neuronal differentiation through p21 mRNA post-transcriptional regulation.

Authors:  Masato Yano; Hirotaka J Okano; Hideyuki Okano
Journal:  J Biol Chem       Date:  2005-01-25       Impact factor: 5.157

8.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

Review 9.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

10.  Targeting β-catenin signaling for therapeutic intervention in MEN1-deficient pancreatic neuroendocrine tumours.

Authors:  Xiuli Jiang; Yanan Cao; Feng Li; Yutong Su; Yanli Li; Ying Peng; Yulong Cheng; Changxian Zhang; Weiqing Wang; Guang Ning
Journal:  Nat Commun       Date:  2014-12-17       Impact factor: 14.919

View more
  8 in total

Review 1.  Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2019-11-27       Impact factor: 4.512

Review 2.  Roles of Embryonic Lethal Abnormal Vision-Like RNA Binding Proteins in Cancer and Beyond.

Authors:  Haijian Cai; Dandan Zheng; Yizhu Yao; Lehe Yang; Xiaoying Huang; Liangxing Wang
Journal:  Front Cell Dev Biol       Date:  2022-04-06

3.  RNA binding protein HuD contributes to β-cell dysfunction by impairing mitochondria dynamics.

Authors:  Youlim Hong; Hyosun Tak; Chongtae Kim; Hoin Kang; Eunbyul Ji; Sojin Ahn; Myeongwoo Jung; Hong Lim Kim; Jeong-Hwa Lee; Wook Kim; Eun Kyung Lee
Journal:  Cell Death Differ       Date:  2019-10-28       Impact factor: 15.828

Review 4.  RNA-Binding Protein HuD as a Versatile Factor in Neuronal and Non-Neuronal Systems.

Authors:  Myeongwoo Jung; Eun Kyung Lee
Journal:  Biology (Basel)       Date:  2021-04-23

Review 5.  Current and New Challenges in the Management of Pancreatic Neuroendocrine Tumors: The Role of miRNA-Based Approaches as New Reliable Biomarkers.

Authors:  Andrei Havasi; Daniel Sur; Simona Sorana Cainap; Cristian-Virgil Lungulescu; Laura-Ioana Gavrilas; Calin Cainap; Catalin Vlad; Ovidiu Balacescu
Journal:  Int J Mol Sci       Date:  2022-01-20       Impact factor: 5.923

6.  Loss of RNA binding protein HuD facilitates the production of the senescence-associated secretory phenotype.

Authors:  Seungyeon Ryu; Myeongwoo Jung; Chongtae Kim; Hoin Kang; Sukyoung Han; Seongho Cha; Seung Min Jeong; Eun Kyung Lee
Journal:  Cell Death Dis       Date:  2022-04-11       Impact factor: 8.469

7.  The Serum MicroRNA Signatures for Pancreatic Cancer Detection and Operability Evaluation.

Authors:  Qiuliang Yan; Dandan Hu; Maolan Li; Yan Chen; Xiangsong Wu; Qinghuang Ye; Zhijiang Wang; Lingzhe He; Jinhui Zhu
Journal:  Front Bioeng Biotechnol       Date:  2020-04-29

Review 8.  Interplay of RNA-Binding Proteins and microRNAs in Neurodegenerative Diseases.

Authors:  Chisato Kinoshita; Noriko Kubota; Koji Aoyama
Journal:  Int J Mol Sci       Date:  2021-05-18       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.